Omalizumab enhances the percentage of GARP cells in both regulatory and terminally differentiated effector Th cells in severe allergic asthmatics

J. Nieto-Fontarigo (Santiago de Compostela, Spain), F. Salgado-Castro (Santiago de Compostela, Spain), M. San-José-Capilla (Santiago de Compostela, Spain), J. Carreira-Villamor (Santiago de Compostela, Spain), L. Valdés-Cuadrado (Santiago de Compostela, Spain), A. Faraldo-García (Santiago de Compostela, Spain), M. García-González (Santiago de Compostela, Spain), C. Diego-Roza (Ferrol, Spain), P. Martín-Lancharro (Santiago de Compostela, Spain), J. Moure-González (Santiago de Compostela, Spain), T. Liñares-Mata (Pontevedra, Spain), E. Takkouche-Souilamas (Santiago de Compostela, Spain), P. Arias (Santiago de Compostela, Spain), M. Nogueira (Santiago de Compostela, Spain), F. González-Barcala (Santiago de Compostela, Spain)

Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD
Session: Novel immunology-based therapies in asthma and COPD
Session type: Oral Presentation
Number: 1649
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Nieto-Fontarigo (Santiago de Compostela, Spain), F. Salgado-Castro (Santiago de Compostela, Spain), M. San-José-Capilla (Santiago de Compostela, Spain), J. Carreira-Villamor (Santiago de Compostela, Spain), L. Valdés-Cuadrado (Santiago de Compostela, Spain), A. Faraldo-García (Santiago de Compostela, Spain), M. García-González (Santiago de Compostela, Spain), C. Diego-Roza (Ferrol, Spain), P. Martín-Lancharro (Santiago de Compostela, Spain), J. Moure-González (Santiago de Compostela, Spain), T. Liñares-Mata (Pontevedra, Spain), E. Takkouche-Souilamas (Santiago de Compostela, Spain), P. Arias (Santiago de Compostela, Spain), M. Nogueira (Santiago de Compostela, Spain), F. González-Barcala (Santiago de Compostela, Spain). Omalizumab enhances the percentage of GARP cells in both regulatory and terminally differentiated effector Th cells in severe allergic asthmatics. 1649

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Activin-A induces human regulatory T cells that control allergic asthma
Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms
Year: 2012

Reduced numbers of circulating CD4+CD25highFOXP3+ regulatory T cells in patients with allergic asthma
Source: Annual Congress 2008 - Understanding airway inflammation
Year: 2008


The role of regulatory T cells in differentiating asthma from COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007

IL-10-producing CD4+ T cells are essential for the development of airway hyperresponsiveness
Source: Annual Congress 2004 - Modulation of the allergic response in animal models
Year: 2004


CD39/CD73 and the imbalance of Th17 and Tregs (regulatory T cells) in allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013

Expression of surface markers on peripheral CD4+CD25high T cells in patients with atopic asthma: role of inhaled corticosteroid
Source: Annual Congress 2008 - Risk factors for asthma versus asthma control
Year: 2008

MiR-1165-3p downregulated in Th2 cells inhibits Th2 differentiation in allergic asthma by targeting PPM1A
Source: International Congress 2019 – Identification of new targets and therapeutic strategies for lung disease
Year: 2019

YS4: Regulation of allergic airway disease by IL-4/IL-13 activated macrophages and dendritic cells
Source: Lung Science Conference 2011 - Immune system dysregulation in chronic lung disease
Year: 2011

The declined CD4+ CD25+Treg cells in patients with moderate to severe asthma associated with over-expressed Th2 response
Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms
Year: 2012

T regulatory cells decrease before asthma exacerbations
Source: Annual Congress 2008 - Understanding the mechanisms and the impact of severe asthma
Year: 2008

Type-2 CD8+ T lymphocytes responsive to PGD2/LTE4 in severe eosinophilic asthma
Source: International Congress 2018 – Advanced profiling of immune cells in chronic lung diseases
Year: 2018




Enhanced expression of IL-18 and increased CD8+ T cells and eosinophils in the airways of asthma death
Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation
Year: 2010


ILC2 cells from severe allergic and eosinophilic asthma demonstrate increased expression of TSLP receptor (TSLPR) and enhanced proliferative capacity.
Source: Virtual Congress 2021 – New insight into the immunology of allergies, asthma and COPD: from mouse to man
Year: 2021


Role of dendritic cells and T-regulatory cells in COPD
Source: Annual Congress 2013 –Immunopathology of COPD: contribution of advancements of new therapeutic agents
Year: 2013


The effects of DC expressing PD-L1 on CD4+ T cell in a murine model of allergic airway disease
Source: Annual Congress 2007 - Mouse models of allergic airway inflammation
Year: 2007


Macrophages induce an allergen-specific and long-term suppression in a mouse asthma model
Source: Eur Respir J 2005; 26: 1040-1046
Year: 2005



Increased T helper lymphocytes and macrophages in peripheral airways of patients with uncontrolled asthma
Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation
Year: 2010


Effects of depletion of CD4+CD25+ T cells with anti-CD25McAb on airway inflammation of asthmatic mice
Source: Eur Respir J 2005; 26: Suppl. 49, 24s
Year: 2005

The effect of Immunotherapy on the expression of costimulatory pathway molecules on dendritic cells and T cells in asthmatic mice
Source: Eur Respir J 2003; 22: Suppl. 45, 483s
Year: 2003

Regulatory T cells suppress more effective th1-induced airway disease compared to Th2 responses
Source: Annual Congress 2009 - Animal models of airways inflammation
Year: 2009